Pulmonary Embolism with MCC or Acute Cor Pulmonale DRG Reimbursement

DRG 175 addresses admissions for pulmonary embolism with Major Complication or Comorbidity or for acute cor pulmonale, signifying high-acuity cases that often require intensive diagnostics and treatment. Correct assignment of this Diagnosis-Related Group is important because it affects Medicare inpatient payment levels and hospital case-mix reporting.

DRG 175 Overview

DRG 175 covers hospital admissions for pulmonary embolism with Major Complication or Comorbidity or for acute cor pulmonale, representing patients with high acuity due to significant respiratory and hemodynamic compromise. This Diagnosis-Related Group groups cases that typically require advanced imaging, anticoagulation or thrombolytic therapy, and potential critical care resources, driving higher resource use and payment. Accurate assignment affects Medicare payment and hospital case-mix index calculations. Coding and documentation that capture the presence of Major Complication or Comorbidity or acute cor pulmonale determine eligibility for this higher-weighted Diagnosis-Related Group.

Acute interventional trials evaluating thrombolytic strategies and procedural approaches for hemodynamically unstable pulmonary embolism (PE) or patients with acute cor pulmonale: these studies focus on critically ill inpatients with massive or high-risk PE to compare systemic thrombolysis, catheter-directed thrombolysis, and embolectomy techniques, assessing short-term outcomes like hemodynamic stabilization, need for mechanical ventilation, and in-hospital mortality. They enroll patients admitted emergently with confirmed PE and right ventricular dysfunction or shock, providing evidence on rapid life‑saving interventions; results directly inform inpatient clinical pathways, ICU resource allocation, and reimbursement decisions for high-cost acute therapies.
Comparative effectiveness studies of anticoagulation regimens and initiation timing in medically stable hospitalized PE patients: these trials examine different anticoagulant classes, dosing strategies, and timing of transition from parenteral to oral agents in patients with submassive PE or PE with comorbidities, measuring recurrent venous thromboembolism, major bleeding, length of stay, and readmission. By targeting the typical DRG 175 population who are admitted but not immediately surgical candidates, this research helps clinicians choose regimens that balance efficacy and safety and helps payers evaluate cost-effectiveness and expected resource use related to drug selection and monitoring.
Post-discharge outcomes and care-coordination studies assessing rehabilitation, follow-up strategies, and secondary prevention in PE patients with prior acute cor pulmonale or major complications: these observational cohorts and pragmatic trials follow patients after hospital discharge to evaluate rates of chronic thromboembolic pulmonary hypertension, functional status, quality of life, recurrent events, and healthcare utilization under different follow-up models (specialized clinics, telemedicine, or primary care-led). This research is relevant for providers and payers because it identifies interventions that reduce readmissions and long-term morbidity in a high-risk DRG cohort, informing bundled payment designs and post-acute care planning.

Acute interventional trials evaluating thrombolytic strategies and procedural approaches for hemodynamically unstable pulmonary embolism (PE) or patients with acute cor pulmonale: these studies focus on critically ill inpatients with massive or high-risk PE to compare systemic thrombolysis, catheter-directed thrombolysis, and embolectomy techniques, assessing short-term outcomes like hemodynamic stabilization, need for mechanical ventilation, and in-hospital mortality. They enroll patients admitted emergently with confirmed PE and right ventricular dysfunction or shock, providing evidence on rapid life‑saving interventions; results directly inform inpatient clinical pathways, ICU resource allocation, and reimbursement decisions for high-cost acute therapies.
Comparative effectiveness studies of anticoagulation regimens and initiation timing in medically stable hospitalized PE patients: these trials examine different anticoagulant classes, dosing strategies, and timing of transition from parenteral to oral agents in patients with submassive PE or PE with comorbidities, measuring recurrent venous thromboembolism, major bleeding, length of stay, and readmission. By targeting the typical DRG 175 population who are admitted but not immediately surgical candidates, this research helps clinicians choose regimens that balance efficacy and safety and helps payers evaluate cost-effectiveness and expected resource use related to drug selection and monitoring.
Post-discharge outcomes and care-coordination studies assessing rehabilitation, follow-up strategies, and secondary prevention in PE patients with prior acute cor pulmonale or major complications: these observational cohorts and pragmatic trials follow patients after hospital discharge to evaluate rates of chronic thromboembolic pulmonary hypertension, functional status, quality of life, recurrent events, and healthcare utilization under different follow-up models (specialized clinics, telemedicine, or primary care-led). This research is relevant for providers and payers because it identifies interventions that reduce readmissions and long-term morbidity in a high-risk DRG cohort, informing bundled payment designs and post-acute care planning.

OpenPayer

Summary & Overview

Pulmonary Embolism with MCC or Acute Cor Pulmonale: Inpatient Reimbursement Overview

DRG 175 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes